{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T15:22:32Z","timestamp":1758640952566,"version":"3.44.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,23]]},"DOI":"10.7759\/cureus.93017","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:32:58Z","timestamp":1758637978000},"source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor (CAR) T Cell Therapy for Neuromuscular Disorders: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno JN","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024, 332:1924-35. 10.1001\/jama.2024.19462","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.10.026","article-title":"CAR T therapy extends its reach to autoimmune diseases","volume":"185","author":"Baker DJ","year":"2022","unstructured":"Baker DJ, June CH. CAR T therapy extends its reach to autoimmune diseases. Cell. 2022, 185:4471-3. 10.1016\/j.cell.2022.10.026","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller F","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al.. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024, 390:687-700. 10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Liu D, Zhang Z, et al.. Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report. J Neurol. 2024, 271:4655-9. 10.1007\/s00415-024-12367-4","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian DS","year":"2024","unstructured":"Tian DS, Qin C, Dong MH, et al.. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol Med. 2024, 16:966-87. 10.1038\/s44321-024-00043-z","journal-title":"EMBO Mol Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T\u00a0cells","volume":"112","author":"Motte J","year":"2024","unstructured":"Motte J, Sgodzai M, Schneider-Gold C, et al.. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T\u00a0cells. Neuron. 2024, 112:1757-63.e2. 10.1016\/j.neuron.2024.04.014","journal-title":"Neuron"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia A","year":"2024","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, et al.. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis. 2024, 83:1597-8. 10.1136\/ard-2024-226017","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101794","article-title":"Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome","volume":"5","author":"Wickel J","year":"2024","unstructured":"Wickel J, Schnetzke U, Sayer-Klink A, et al.. Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep Med. 2024, 5:101794. 10.1016\/j.xcrm.2024.101794","journal-title":"Cell Rep Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03564-1","article-title":"CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?","volume":"27","author":"Jouret M","year":"2025","unstructured":"Jouret M, Viel S, Fournier B, Benezech S, Avouac J, Scherlinger M, Belot A. CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?. Arthritis Res Ther. 2025, 27:102. 10.1186\/s13075-025-03564-1","journal-title":"Arthritis Res Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai R","year":"2024","unstructured":"Nicolai R, Merli P, Moran Alvarez P, et al.. Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis Rheumatol. 2024, 76:1560-5. 10.1002\/art.42933","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial","volume":"32","author":"Volkov J","year":"2024","unstructured":"Volkov J, Nunez D, Mozaffar T, et al.. Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial. Mol Ther. 2024, 32:3821-8. 10.1016\/j.ymthe.2024.09.009","journal-title":"Mol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.7240","article-title":"CD19-targeting CAR T-cell therapy for antisynthetase syndrome","volume":"329","author":"Lundberg IE","year":"2023","unstructured":"Lundberg IE, Galindo-Feria AS, Horuluoglu B. CD19-targeting CAR T-cell therapy for antisynthetase syndrome. JAMA. 2023, 329:2130-1. 10.1001\/jama.2023.7240","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher AC","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, et al.. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023, 329:2154-62. 10.1001\/jama.2023.8753","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf190","article-title":"A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review","volume":"64","author":"Haase I","year":"2025","unstructured":"Haase I, Richter J, Holzer MT, et al.. A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review. Rheumatology (Oxford). 2025, 64:5101-7. 10.1093\/rheumatology\/keaf190","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy","volume":"6","author":"Dong MH","year":"2025","unstructured":"Dong MH, Mei ZC, Zhou LQ, et al.. Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy. Med. 2025, 6:100704. 10.1016\/j.medj.2025.100704","journal-title":"Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins S","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019, 94:S3-9. 10.1002\/ajh.25418","journal-title":"Am J Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner RC","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021, 11:69. 10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett G","year":"2024","unstructured":"Schett G, M\u00fcller F, Taubmann J, et al.. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol. 2024, 20:531-44. 10.1038\/s41584-024-01139-z","journal-title":"Nat Rev Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg IE","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al.. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021, 7:86. 10.1038\/s41572-021-00321-x","journal-title":"Nat Rev Dis Primers"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang X","year":"2024","unstructured":"Wang X, Wu X, Tan B, et al.. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024, 187:4890-904.e9. 10.1016\/j.cell.2024.06.027","journal-title":"Cell"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt LJ","year":"2016","unstructured":"Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016, 23:218-26. 10.1097\/CPM.0000000000000171","journal-title":"Clin Pulm Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller F","year":"2025","unstructured":"M\u00fcller F, Wirsching A, Hagen M, et al.. BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med. 2025, 31:1793-7. 10.1038\/s41591-025-03718-3","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann J","year":"2024","unstructured":"Taubmann J, Knitza J, M\u00fcller F, et al.. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024, 63:e12-4. 10.1093\/rheumatology\/kead330","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100676","article-title":"CD19 CAR-T cell therapy in a pediatric patient with MDA5(+) dermatomyositis and rapidly progressive interstitial lung disease","volume":"6","author":"Par\u00eds-Mu\u00f1oz A","year":"2025","unstructured":"Par\u00eds-Mu\u00f1oz A, Alcobendas-Rueda RM, Verd\u00fa-S\u00e1nchez C, et al.. CD19 CAR-T cell therapy in a pediatric patient with MDA5(+) dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025, 6:100676. 10.1016\/j.medj.2025.100676","journal-title":"Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406593-chimeric-antigen-receptor-car-t-cell-therapy-for-neuromuscular-disorders-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:33:31Z","timestamp":1758638011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406593-chimeric-antigen-receptor-car-t-cell-therapy-for-neuromuscular-disorders-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.93017","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}